Revenue Update on Kamada Ltd(NASDAQ:KMDA)

Kamada Ltd(NASDAQ:KMDA) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Feb 6, 2017. Company reported revenue of $24.258M. Analysts estimated a revenue of $24.000M. The revenues were 1.08% above the estimates. Earnings per share were $-0.05. The reported EPS was below estimates by -600%. Analysts had estimated an EPS of $0.01.

Kamada Ltd (KMDA) made into the market gainers list on Tuesdays trading session with the shares advancing 0.92% or 0.06 points. Due to strong positive momentum, the stock ended at $6.55, which is also near the day’s high of $6.6. The stock began the session at $6.5 and the volume stood at 14,291 shares. The 52-week high of the shares is $6.7 and the 52 week low is $3.26. The company has a current market capitalization of $239 M and it has 3,64,19,189 shares in outstanding.

Kamada Ltd. is an Israel-based biopharmaceutical company which develops produces and markets therapeutics based on chromatographic purification technology. It offers bio-therapeutics for human use such as specialty proteins specific immunoglobulins and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Share this post

Leave a Reply